Celgene European Panel Recommends Against Revlimid for MDS

January 25, 2008 |

1 min read

NEW YORK, Jan 24 (Reuters) - Celgene Corp said on Thursday an advisory panel for European health regulators recommended Revlimid not be approved in Europe for myelodysplastic syndrome patients with anemia, citing safety concerns.

Regulatory

MORE ON THIS TOPIC

NIAID Director Dr. Jeanne Marrazzo addresses staff. She is wearing a black and white shirt, black pants, and round glasses.

Regulatory

Fired NIAID Director Claims Ouster Was Payback for Whistleblower Report

October 3, 2025

·

2 min read

·

Tristan Manalac

Stack of coins balancing on seesaw over a bottle of pills.

Drug pricing

CMS Finalizes Stronger Protections for Orphan Drugs Against IRA Price Negotiations

October 3, 2025

·

2 min read

·

Tristan Manalac

Trendy halftone collage. Concept of choice, make a decision left or right, ability to think in a difficult situation, question of choosing between 2 directions. Illustration for web banner, social media banner. Vector illustration

Tariffs

Trump Delays Pharma Tariffs Yet Again

October 2, 2025

·

2 min read

·

Tristan Manalac

Difficult question concept. Big question mark or big problem to solve or finding solution, doubt or uncertainty, thinking to make decision, businessman holds up big question mark.

Drug pricing

Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access

October 1, 2025

·

2 min read

·

Dan Samorodnitsky